Bisphosphonates in the Treatment of Osteoporosis: a Review of Their Contribution and Controversies

Overview

Journal Skeletal Radiol

Specialties Orthopedics
Radiology

Date 2011 Aug 18

PMID 21847749

Citations 11

Authors

Ian R Reid

Affiliations

Soon will be listed here.

Abstract

The bisphosphonates have revolutionized the therapy of osteoporosis, particularly the prevention of vertebral and hip fractures. The development of tools for defining absolute fracture risk facilitates their targeting to appropriate, at-risk individuals. Prescribers need to be aware of their common side effects (gastrointestinal intolerance with oral dosing and flu-like illness following intravenous use). Whether these agents carry a real risk of other problems such as osteonecrosis of the jaw and subtrochanteric fractures remains uncertain at the present time. If the association of these problems with bisphosphonates is real, it is important that the major therapeutic benefits that can accrue from bisphosphonates' appropriate targeted use are not lost as a result of the anxiety concerning these extremely rare adverse events.

Citing Articles

A Mendelian randomization study for drug repurposing reveals bezafibrate and fenofibric acid as potential osteoporosis treatments.

Li X, Pang W, Zhang Y, Liu D, Yi Q, Wang N Front Pharmacol. 2023; 14:1211302.

PMID: 37547327 PMC: 10397407. DOI: 10.3389/fphar.2023.1211302.

Oral Bisphosphonates Are Associated With Increased Risk of Severe Acute Kidney Injury in Elderly Patients With Complex Health Needs: A Self-Controlled Case Series in the United Kingdom.

Oda T, Jodicke A, Robinson D, Delmestri A, Keogh R, Prieto-Alhambra D J Bone Miner Res. 2022; 37(7):1270-1278.

PMID: 35579494 PMC: 9543096. DOI: 10.1002/jbmr.4573.

7,8-Dihydroxyflavone modulates bone formation and resorption and ameliorates ovariectomy-induced osteoporosis.

Xue F, Zhao Z, Gu Y, Han J, Ye K, Zhang Y Elife. 2021; 10.

PMID: 34227467 PMC: 8285109. DOI: 10.7554/eLife.64872.

Fall Prevention and Anti-Osteoporosis in Osteopenia Patients of 80 Years of Age and Older: A Randomized Controlled Study.

Zhou J, Liu B, Qin M, Liu J Orthop Surg. 2020; 12(3):890-899.

PMID: 32495521 PMC: 7307256. DOI: 10.1111/os.12701.

Gorham-Stout disease: good results of bisphosphonate treatment in 6 of 7 patients.

Schneider K, Masthoff M, Gosheger G, Klingebiel S, Schorn D, Roder J Acta Orthop. 2020; 91(2):209-214.

PMID: 31928107 PMC: 7144312. DOI: 10.1080/17453674.2019.1709716.

References

Reid I, Heap S, King A, IBBERTSON H . Two-year follow-up of biphosphonate (APD) treatment in steroid osteoporosis. Lancet. 1988; 2(8620):1144. DOI: 10.1016/s0140-6736(88)90566-1. View

Fleisch H, Russell R, Francis M . Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science. 1969; 165(3899):1262-4. DOI: 10.1126/science.165.3899.1262. View

Recker R, Delmas P, Halse J, Reid I, Boonen S, Garcia-Hernandez P . Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res. 2007; 23(1):6-16. DOI: 10.1359/jbmr.070906. View

Watts N, Chines A, Olszynski W, McKeever C, McClung M, Zhou X . Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int. 2007; 19(3):365-72. DOI: 10.1007/s00198-007-0460-7. View

Black D, Schwartz A, Ensrud K, Cauley J, Levis S, Quandt S . Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006; 296(24):2927-38. DOI: 10.1001/jama.296.24.2927. View

Reid I, King A, Alexander C, IBBERTSON H . Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Lancet. 1988; 1(8578):143-6. DOI: 10.1016/s0140-6736(88)92721-3. View

Cardwell C, Abnet C, Cantwell M, Murray L . Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA. 2010; 304(6):657-63. PMC: 3513370. DOI: 10.1001/jama.2010.1098. View

Reid I . Osteonecrosis of the jaw: who gets it, and why?. Bone. 2008; 44(1):4-10. DOI: 10.1016/j.bone.2008.09.012. View

Fleisch H, Russell R, Simpson B, Muhlbauer R . Prevention by a diphosphonate of immobilization "osteoporosis" in rats. Nature. 1969; 223(5202):211-2. DOI: 10.1038/223211a0. View

10.

Black D, Kelly M, Genant H, Palermo L, Eastell R, Bucci-Rechtweg C . Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med. 2010; 362(19):1761-71. DOI: 10.1056/NEJMoa1001086. View

11.

Lyles K, Colon-Emeric C, Magaziner J, Adachi J, Pieper C, Mautalen C . Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007; 357(18):1799-809. PMC: 2324066. DOI: 10.1056/NEJMoa074941. View

12.

Bolland M, Grey A, Horne A, Briggs S, Thomas M, Ellis-Pegler R . Effects of intravenous zoledronate on bone turnover and BMD persist for at least 24 months. J Bone Miner Res. 2008; 23(8):1304-8. DOI: 10.1359/jbmr.080312. View

13.

Altman R, JOHNSTON C, Khairi M, Wellman H, Serafini A, Sankey R . Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans). N Engl J Med. 1973; 289(26):1379-84. DOI: 10.1056/NEJM197312272892601. View

14.

Lenart B, Lorich D, Lane J . Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med. 2008; 358(12):1304-6. DOI: 10.1056/NEJMc0707493. View

15.

Valkema R, Vismans F, Papapoulos S, Pauwels E, BIJVOET O . Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD. Bone Miner. 1989; 5(2):183-92. DOI: 10.1016/0169-6009(89)90095-0. View

16.

Wysowski D . Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med. 2009; 360(1):89-90. DOI: 10.1056/NEJMc0808738. View

17.

Abrahamsen B, Eiken P, Eastell R . More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med. 2009; 360(17):1789. DOI: 10.1056/NEJMc096026. View

18.

Marcus R, Wong M, Heath 3rd H, Stock J . Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocr Rev. 2002; 23(1):16-37. DOI: 10.1210/edrv.23.1.0453. View

19.

Frijlink W, BIJVOET O, te Velde J, Heynen G . Treatment of Paget's disease with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.). Lancet. 1979; 1(8120):799-803. DOI: 10.1016/s0140-6736(79)91318-7. View

20.

Karam R, Camm J, McClung M . Yearly zoledronic acid in postmenopausal osteoporosis. N Engl J Med. 2007; 357(7):712-3. View